A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects six to seven million people in Latin America. Lately, it has become an emerging public health concern in nonendemic regions such as North America and Europe. There is no prophylactic or therapeutic vaccine as yet,...

Descripción completa

Detalles Bibliográficos
Autores principales: Portillo, Susana, Zepeda, Brenda G., Iniguez, Eva, Olivas, Janet J., Karimi, Nasim H., Moreira, Otacilio C., Marques, Alexandre F., Michael, Katja, Maldonado, Rosa A., Almeida, Igor C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430786/
https://www.ncbi.nlm.nih.gov/pubmed/30911415
http://dx.doi.org/10.1038/s41541-019-0107-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430786/
https://www.ncbi.nlm.nih.gov/pubmed/30911415
http://dx.doi.org/10.1038/s41541-019-0107-7

Ejemplares similares